Dendreon Corp fka DNDNQ

[spartex]

I agree, but if he appeals the likely outcome may be another slaughtered DNDN lamb. Will an appeal tarnish their already established relationship with the FDA? Or maybe that went out the window with the approvable letter? It's a doubled-edged decision, and Mitch must certainly understand the political environment he faces with such a decision. I understand the value in standing up for the company's science and patients in need of a Provenge therapy, but the question is whether this is a battle worth fighting at this time?